Related Experiment Video

Updated: May 22, 2026

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

Novel therapies in glioblastoma

James Perry1, Masahiko Okamoto, Michael Guiou

  • 1Department of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.

Neurology Research International
|April 25, 2012
PubMed

Insights

Glioblastoma treatments show limited progress, with current standard therapies offering minimal survival gains. Novel targeted therapies are explored, but monotherapies are ineffective due to redundant pathways in glioblastoma multiforme (GBM).

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer therapeutics

Background:

  • Conventional glioblastoma (GBM) treatment (surgery, radiation, chemotherapy) has shown incremental advances over 30 years, resulting in poor patient outcomes and a median survival of approximately 15 months.
  • Molecular biology has identified key pathways (e.g., receptor tyrosine kinases [RTKs], PI3K/AKT/mTOR, angiogenesis) crucial in GBM tumorigenesis, treatment resistance, and disease progression.

Purpose of the Study:

  • To review novel therapeutic strategies for glioblastoma.
  • To analyze the successes and failures of targeted therapies in GBM.
  • To highlight the need for improved understanding of GBM biology for optimized treatment strategies.

Main Methods:

  • Literature review of conventional and novel glioblastoma therapies.
  • Analysis of molecular pathways implicated in glioblastoma.
  • Evaluation of targeted therapy efficacy and limitations.

Main Results:

  • Monotherapies for glioblastoma have yielded limited clinical benefits.
  • Functional redundancy among GBM pathways contributes to the ineffectiveness of single-agent treatments.
  • Despite advances in understanding GBM biology, targeted therapies have often fallen short of expectations.

Conclusions:

  • Targeted therapies alone show minor results in glioblastoma treatment.
  • Understanding complex GBM networks is crucial for developing effective therapeutic strategies.
  • Combination therapies or strategies addressing pathway redundancy may improve treatment outcomes for glioblastoma.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...